Fagan Susan C, Edwards David J, Borlongan Cesar V, Xu Lin, Arora Ankur, Feuerstein Giora, Hess David C
Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 30912-2450, USA.
Exp Neurol. 2004 Apr;186(2):248-51. doi: 10.1016/j.expneurol.2003.12.006.
Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.
米诺环素目前正在作为一种神经保护剂用于多种不同的脑部疾病的研究。在十多项针对各种脑损伤模型的实验研究中，已通过腹腔注射给予高剂量的米诺环素。本报告详细阐述了关于这种给药途径的新问题，并提出在实验动物中采用静脉给药的理由，特别是对于急性神经保护，以优化药物向脑部的递送并促进向人体研究的转化。
